ROR2 and breast carcinoma: This has since been confirmed in several solid tumor entities in which knockdown of ROR2 resulted in decreased migration and/or invasion, e.g., in mesothelioma [57], melanoma [79], renal cancer [89], breast cancer [114], ovarian cancer [59,99,116,117], prostate cancer [118], leiomyosarcoma, gastrointestinal stroma tumors [62], and osteosarcoma [61].